Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Fusion-VAC-XS15

Phase 1Small molecule

UUniversity Hospital Tuebingen

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune Checkpoint InhibitionRecruiting

Immune Checkpoint InhibitionPhase 1

Recruiting

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Immune Checkpoint Inhibition

NCT05937295

Clinical

Trials by Indication[1]

Immune Checkpoint Inhibition1 trial

FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition

Recruiting·UUniversity Hospital Tuebingen·Phase 1·NCT05937295·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Fusion-VAC-XS15. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fusion-VAC-XS15 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fusion-VAC-XS15. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital Tuebingen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity Hospital Tuebingen

Related News